BACKGROUND: @entity2533 ( @entity2533 ) signalling is involved in both @entity5 suppression and @entity5 progression. The mRNA expression levels of the @entity2533 isoforms and receptors in @entity0 may have prognostic value and clinical implications. METHODS: The mRNA levels of @entity2533 , @entity6474 , @entity1934 , @entity7382 and @entity2534 were analysed in primary @entity0 and adjacent normal breast tissues, and the associations with @entity5 characteristics and @entity1 ' overall and relapse-free survival were evaluated, using the public gene expression microarray data from The Cancer Genome Atlas (n   =   520) and the Gene Expression Omnibus (four datasets) and our quantitative real-time PCR validation data (n   =   71). RESULTS: Significantly higher @entity2533 and @entity1934 mRNA levels and lower @entity2534 mRNA levels were observed in primary @entity5 compared with their paired normal tissues. @entity2533 mRNA expression was seemly lower in @entity5 and in @entity5 from lymph node-negative @entity1 . @entity1934 mRNA expression was significantly lower in @entity172 receptor-negative/ @entity1420 receptor-negative/Basal-like/Grade 3 @entity5 . High @entity6474 , @entity1934 and @entity2534 mRNA levels in @entity5 were generally associated with better prognosis for @entity1 , especially those diagnosed with lymph node-negative diseases. High @entity7382 mRNA levels in @entity5 were associated with poorer clinical outcomes for @entity1 diagnosed with small (diameter  <=2  cm) @entity5 . CONCLUSIONS: The results indicate a reduced responsiveness of @entity5 cells to @entity2533 , a preferential up-regulation of @entity2533 in @entity5 and a preferential up-regulation of @entity1934 in @entity5 . The results may not only provide prognostic value for @entity1 but also assist in classifying @entity5 according to their potential responses to @entity2533 and selecting @entity1 for @entity2533 signalling pathway targeted therapies.

@entity2533 isoforms and receptors mRNA expression in XXXX : prognostic value and clinical implications.

@entity7382 :: ('7046', 'Gene') :: ['TGFBR1'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast tumours'] @entity2534 :: ('7048', 'Gene') :: ['TGFBR2'] @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant tumours', 'triple-negative tumours', 'tumours', 'premalignant tumours', 'tumour'] @entity2533 :: ('7040', 'Gene') :: ['TGFB1', 'TGFb', 'Transforming growth factor beta'] @entity1934 :: ('7043', 'Gene') :: ['TGFB3'] @entity6474 :: ('7042', 'Gene') :: ['TGFB2']
@entity0 :: (MESH:D001943,Disease) :: ['breast tumours']
